WO2022010206A1 - Système de mise en quarantaine pour maladie infectieuse à haut risque à l'aide d'un diagnostic moléculaire à base d'amplification isotherme - Google Patents

Système de mise en quarantaine pour maladie infectieuse à haut risque à l'aide d'un diagnostic moléculaire à base d'amplification isotherme Download PDF

Info

Publication number
WO2022010206A1
WO2022010206A1 PCT/KR2021/008506 KR2021008506W WO2022010206A1 WO 2022010206 A1 WO2022010206 A1 WO 2022010206A1 KR 2021008506 W KR2021008506 W KR 2021008506W WO 2022010206 A1 WO2022010206 A1 WO 2022010206A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
primer
quarantine system
test
covid
Prior art date
Application number
PCT/KR2021/008506
Other languages
English (en)
Korean (ko)
Inventor
박성민
Original Assignee
주식회사 시선바이오머티리얼스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 시선바이오머티리얼스 filed Critical 주식회사 시선바이오머티리얼스
Publication of WO2022010206A1 publication Critical patent/WO2022010206A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/101—Temperature
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a quarantine and quarantine system for a high-risk infectious disease, Corona 19 virus, and more specifically, Corona 19 quarantine using isothermal amplification-based molecular diagnostics for SARS-CoV-2 detection It relates to the system, especially the quarantine system in airports, ports, large gatherings, and cluster infection areas.
  • Coronaviruses are known to cause a variety of diseases in animals, such as gastrointestinal and respiratory diseases.
  • Human coronaviruses that infect humans are HCoV-229E and HCoV-OC43 discovered in the 1960s, and HCoV-NL63 (2004) and HCoV-HKU1 (2005) discovered after the SARS pandemic, which are generally not associated with upper respiratory tract infections. It is known that it can lead to serious lung disease in immunodeficiency patients. It is reported that the infection rate for coronavirus increases mainly in winter or early spring, and it is known that the proportion of the pathogen that is the cause of the coronavirus among adult cold patients is quite high.
  • SARS-CoV which causes Severe Acute Respiratory Syndrome (SARS)
  • WHO World Health Organization
  • HCV-EMC Middle East Respiratory Syndrome Coronavirus
  • Coronavirus Infectious Disease-19 is a viral respiratory disease that occurred in Wuhan, China in December 2019. It is also called 'Wuhan pneumonia', 'novel coronavirus infection', 'corona 19'. It is an epidemic disease caused by the novel coronavirus, which is transmitted through the respiratory tract, and shows strong contagious characteristics in the early stages of infection with few symptoms. After infection, symptoms such as sore throat, high fever, cough, and shortness of breath develop into pneumonia. After it spread worldwide in March 2020, the World Health Organization declared the disease a pandemic.
  • Coronavirus Infectious Disease-19 (Covid-19) is mainly transmitted through the respiratory tract. When infected, the virus invades the lungs, causing symptoms such as high fever, coughing, and shortness of breath, and after showing symptoms similar to pneumonia, in severe cases, the alveoli are damaged, leading to death from respiratory failure.
  • the incubation period is 3 to 7 days, but can last up to 14 days. On January 30, 2020, China announced that there were cases where the incubation period was extended to 23 days. It has been reported that COVID-19 is transmitted even during the incubation period when symptoms do not appear.
  • SARS-CoV-2 which currently causes novel coronavirus infection (COVID-19), is basically diagnosed by 'conventional PCR' and sequencing analysis.
  • the pan-coronavirus test method first tests for the presence or absence of all coronaviruses, including the novel coronavirus, and if it is negative, it means that it is not a coronavirus infection. If it is positive, it is determined whether it is another coronavirus causing a cold or a novel coronavirus through gene sequencing. Therefore, it takes 1 to 2 days for diagnosis.
  • the Korea Centers for Disease Control and Prevention (KCDC) is carrying out special quarantine for domestic and foreign nationals entering Korea in order to block the entry of people infected with COVID-19 from overseas.
  • KCDC Korea Centers for Disease Control and Prevention
  • the special entry procedure involves filling out a health status questionnaire and special quarantine report on board the aircraft before entering the country, temperature check at the arrival hall quarantine, submitting a health status questionnaire, and checking for symptoms. quarantined, collecting samples and conducting diagnostic tests.
  • a 'mobile self-diagnosis app' is installed to monitor health conditions such as fever and cough for 14 days after entry.
  • An object of the present invention is a quarantine system using the AQ-TOP TM COVID-19 Rapid kit to quickly screen a person infected with or suspected of being infected with the COVID-19 virus, specifically a new airport, port named 4S (Seasun Smart Shield System) , to provide a quarantine system for large gatherings and cluster infection areas.
  • 4S Seasun Smart Shield System
  • the present invention provides a COVID-19 quarantine system using AQ-TOP TM COVID-19 Rapid kit for detecting SARS-CoV-2, in particular, a quarantine system for airports, ports, large gatherings, mass infection areas, etc. do.
  • 1 is a schematic representation of the current state of the existing COVID-19 test product.
  • FIG. 3 shows a pulling test method in the quarantine system according to the present invention.
  • FIG. 4 shows a single test method in the quarantine system according to the present invention.
  • FIG 5 shows an emergency test method in the quarantine system according to the present invention.
  • a quarantine system that can perform large-scale quarantine faster and faster than the existing method has been developed, and a primer pair capable of amplifying the ORF1ab gene and N gene of SARS-CoV-2 virus, and the primer pair amplified by the
  • This is a gene amplification method that uses a PNA probe that can detect products with high sensitivity and specificity.
  • a quarantine system applied with the "Seasun Smart Shield System (4S)" was developed.
  • the present invention relates to a COVID-19 quarantine system using AQ-TOPTM COVID-19 Rapid Kit for SARS-CoV-2 detection.
  • the present invention is a COVID-19 quarantine system using a molecular diagnostic method through gene amplification, and in particular, it is preferable to use an isothermal amplification-based molecular diagnostic method, but is not limited thereto.
  • the airport quarantine system consists of entry inspection, departure inspection, and emergency inspection. As an inspection, many inspections must be performed in a short time.
  • the pooling test (pooling test), the single test (single test) and the emergency test (emergency test) are all identification steps; sampling step; virus isolation step; And it may be characterized in that it proceeds to the diagnosis / analysis step (FIG. 2).
  • the pooling test, the single test, and the emergency test all require an identification step, and all require a clinical examination diagnosis consent form and an individual identification tag, and the clinical examination
  • a clinical examination diagnosis consent form and an individual identification tag For example, in the case of entering from the airport, it is desirable to collect the consent form after distributing it on board, and in the case of departure inspection, it is desirable to distribute and collect it in the dedicated waiting room.
  • the individual identification tag may be performed by attaching a sticker to a bracelet or identification card (passport, resident registration card, driver's license, etc.) (FIG. 3).
  • the pooling test is characterized in that it is carried out in a manner in which three or four samples are put into one tube and tested.
  • the pooling test is performed with a Big Screening system in which 3 to 4 specimens are placed in one VTM tube and designated as one group for inspection. It can test 760 people in an hour, and additional detailed tests are required to confirm the infection.
  • the Big Screening system uses the Top TM Virus Collection kit (Sisun Biomaterials, Korea), and after collecting the virus, the Top TM Vrial DNA/RNA Exraction Kit (Sissun Biomaterials, Korea) is used. was used to isolate virus DNA and RNA, and SARS-CoV-2 was detected using AQ-TOP TM CIVID-19 Rapid Kit (Sisun Biomaterials, Korea), and gene amplification was performed by CFX96 (Bio-Rad). Alternatively, amplification is performed using an ABI7500 (ABI) instrument (Table 1).
  • the sample odor of the pooling test upon entry at the airport is 37.5 ° C or less according to the fever standard (37.5 ° C), "Oral swab”, 37.5 ° C or more Sampling is carried out with a “Nasal swab”, and a medical professional and flight attendant accompany them to collect a sample at the Connection Bridge, and collect samples by grouping 1 row-1 for each seat in the cabin (4 people/tube) It is preferable to proceed with
  • the "virus isolation step” proceeds with an automatic magnetic bead system (Automation Magnetic bead System), and it is preferable that it takes about 20 minutes to proceed with the 48 test.
  • an automatic magnetic bead system Automation Magnetic bead System
  • the "diagnosis/analysis step" of the pooling test is performed using AQ-TOPTM COVID-19 Rapid Kit (Sightsun Biomaterials, Korea) and CFX96 or CFX384 equipment (Bio-Rad or ABI). Apply to proceed with PCR amplification. It is preferable that it takes about 30 minutes.
  • the single test is characterized in that the test is performed by putting one specimen in one tube as a single test (FIG. 4).
  • a single test enables a quick result report and a smooth end of a situation through a quick and accurate test.
  • the single test is carried out with the Urgent Screening system in which a single test system is applied 1:1 by putting one specimen into one VTM tube, and accurate diagnosis is possible in a short time, Up to 64 people can be tested in 30 minutes.
  • the Urgent Screening system uses the Top TM Virus Collection kit (Siksun Biomaterials, Korea), and after collecting the virus, the Top TM Vrial DNA/RNA Exraction Kit (Sissun Biomaterials, Korea) is used. isolates the DNA and RNA of the virus, and detects SARS-CoV-2 using the AQ-TOP TM COVID-19 Rapid Kit (Sisun Biomaterials, Korea), s, Korea) and PCR amplification takes about 15 minutes (Table 2).
  • 37.5°C or less passes the single test, and 37.5°C or more is sampled with a “Nasal swab” and collect samples in the waiting room with specialized medical personnel.
  • the "virus isolation step” proceeds with an automatic magnetic bead system (Automation Magnetic bead System), and it is preferable that it takes about 20 minutes to proceed with the 48 test.
  • an automatic magnetic bead system Automation Magnetic bead System
  • the "diagnosis/analysis step" of the single test is PCR by applying AQ-TOPTM COVID-19 Rapid Kit (SEASUN) and Sesun Bio isothermal amplification equipment (Seasun Biomaterials, Korea) It is preferable that the amplification process takes about 15 minutes.
  • the emergency test is characterized in that the test is performed by putting one specimen in one tube as a single test (FIG. 5).
  • the emergency test prevents/isolates the spread of infection in indoor facilities and areas in advance so that the examination for infectious diseases can be carried out smoothly with a rapid and accurate quarantine system, Subjects are tested primarily, and groups that are positive for infectious diseases through pooling test are targeted.
  • the urgent test is carried out by an urgent screening system that applies a single test system that is conducted 1:1 by putting one specimen into one VTM tube, and accurate diagnosis is possible in a short time, Up to 64 people can be tested in 30 minutes.
  • the Urgent Screening system uses the Top TM Virus Collection kit (Siksun Biomaterials, Korea), and after collecting the virus, the Top TM Vrial DNA/RNA Exraction Kit (Sissun Biomaterials, Korea) is used. isolates the DNA and RNA of the virus, and detects SARS-CoV-2 using the AQ-TOP TM COVID-19 Rapid Kit (Sisun Biomaterials, Korea), s, Korea) and PCR amplification takes about 15 minutes (Table 2).
  • the "virus isolation step” proceeds with an automatic magnetic bead system, and it is preferable that it takes about 20 minutes to proceed with the 48 test. Alternatively, it proceeds with the Column/Syringe System. and preferably 10 minutes per 24 tests or 10 minutes per 10 tests.
  • the "diagnosis/analysis step" of the emergency test is PCR amplification by applying AQ-TOPTM COVID-19 Rapid Kit (SEASUN) and SEASUN Bio Isothermal Amplification Equipment (Seasun Biomaterials, Korea), Preferably, it takes about 15 minutes.
  • the departure inspection and the emergency inspection may be characterized by performing isothermal amplification PCR using the AQ-TOPTM COVID-19 Rapid Kit.
  • the emergency test be performed on a positive discriminant in a pooling test.
  • the sample collection may be characterized in that it is collected through the oral cavity (Oral) or the nasal cavity (Nasal).
  • a sample with a body temperature of 37.5° C. or lower is collected through the oral cavity, and a sample with a body temperature of 37.5° C. or higher and suspected symptoms is collected through the nasal cavity.
  • the AQ-TOP TM COVID-19 Rapid Kit may be characterized by including a primer pair for SARS-CoV-2 gene amplification selected from the following (i) to (xi):
  • (x) a primer pair consisting of a forward primer of SEQ ID NO: 19 and a reverse primer of SEQ ID NO: 20;
  • (xi) a primer pair consisting of a forward primer of SEQ ID NO: 21 and a reverse primer of SEQ ID NO: 22.
  • the AQ-TOP TM COVID-19 Rapid Kit may include a PNA probe for diagnosis of SARS-CoV-2 represented by one or more sequences selected from the group consisting of SEQ ID NOs: 23-30. .
  • the quarantine system of the present invention is a quarantine system, characterized in that it is performed at an airport, a port, or a large-scale facility.
  • the primer pair included in the AQ-TOPTM COVID-19 Rapid Kit is a primer pair capable of amplifying the ORF1ab gene and N gene of SARS-CoV-2 virus, and amplified by the primer pair The amplified product is detected by the PNA probe of SEQ ID NOs: 33 to 48.
  • the PNA probe is not limited, but may be characterized in that a reporter or a quencher is bound.
  • the probe of the present invention may bind to both ends of a reporter and a fluorescent material of a quencher capable of quenching reporter fluorescence, and may include an intercalating fluorescent material.
  • the reporter may be one or more selected from the group consisting of FAM (6-carboxyfluorescein), HEX, Texas red, JOE, TAMRA, CY5, CY3, Alexa680, and the quencher is TAMRA (6-carboxytetramethyl-rhodamine), BHQ1, It is preferred, but not limited to, BHQ2 or Dabcyl.
  • the intercalating fluorescent material is acridine homodimer and its derivatives, acridine orange and its derivatives, 7-aminoactinomycin D (7-AAD) and derivatives thereof, Actinomycin D and derivatives thereof, ACMA (9-amino-6-chloro-2-methoxyacridine) and derivatives thereof, DAPI and derivatives thereof, dihydroethidium (Dihydroethidium) and its derivatives, ethidium bromide and its derivatives, ethidium homodimer-1 (EthD-1) and its derivatives, ethidium homodimer-2 (EthD-2) and its derivatives, ethidium Ethidium monoazide and its derivatives, Hexidium iodide and its derivatives, bisbenzimide (Hoechst 33258) and its derivatives, Hoechst 33342 and its derivatives, ho Hoechst 34580 and its derivatives, hydroxystilbamidine and its derivatives, LDS
  • the AQ-TOPTM COVID-19 Rapid Kit is a control material; a primer pair of a forward primer of SEQ ID NO: 31 and a reverse primer of SEQ ID NO: 32, a primer pair of a forward primer of SEQ ID NO: 33 and a reverse primer of SEQ ID NO: 34 for detecting this; And it may be characterized in that it further comprises a PNA probe of SEQ ID NOs: 35-37, but is not limited thereto.
  • the internal control material can be used without limitation as long as it is a gene that can confirm the success or failure of the polymerase chain reaction in a clinical specimen regardless of the presence or absence of SARS-CoV-2, but preferably a homosapiens species Rnase P gene It may be characterized as an RNA region of
  • the diagnosis/analysis step is preferably performed as the following step.
  • the specimen sample is a DNA or RNA molecule, and the molecule may be in a double-stranded or single-stranded form.
  • the nucleic acid as an initial material is single-stranded RNA
  • cDNA complementary DNA
  • the nucleic acid as a starting material is double-stranded, it is preferable to make the two strands into a single-stranded or partially single-stranded form.
  • Methods known to separate strands include, but are not limited to, heat, alkali, formamide, urea and glycoxal treatment, enzymatic methods (eg, helicase action) and binding proteins.
  • strand separation can be achieved by heat treatment at a temperature of 80°C to 105°C.
  • the gene is not limited, but may be the ORF1ab gene or N gene of SARS-CoV-2.
  • the analysis method is not limited, but it may be characterized in that it is performed by PCR, reverse transcription real time PCR, or isothermal amplification PCR method.
  • step b) may be characterized in that it further comprises a control material.
  • the internal control material can be used without limitation as long as it is a gene that can confirm the success of the reverse transcription polymerase chain reaction in a clinical sample regardless of the presence or absence of the novel coronavirus (SARS-CoV-2), but preferably It can be characterized as an RNA region of the homosapiens species RNase P gene.
  • SARS-CoV-2 novel coronavirus
  • the 'target nucleic acid', 'synthetic DNA' or 'artificial oligo' of the present invention means a nucleic acid sequence to be detected, and the nucleic acid sequence of a 'target gene' encoding a protein having physiological and biochemical functions. It contains a specific site and is annealed or hybridized with a primer or probe under hybridization, annealing or amplification conditions.
  • Hybridization' in the present invention means that complementary single-stranded nucleic acids form double-stranded nucleic acids. Hybridization may occur when complementarity between two nucleic acid strands is perfect (perfect match) or even when some mismatched bases are present. The degree of complementarity required for hybridization may vary depending on hybridization conditions, and in particular may be controlled by temperature.
  • the PNA probe containing the reporter and quencher of the present invention generates a fluorescent signal after hybridization with the target nucleic acid, and the presence or absence of the target nucleic acid can be detected through analysis.
  • Example 1 Preparation of primers and detection probes for SARS-CoV-2 gene amplification
  • primers of SEQ ID NOs: 1 to 18 were prepared as shown in Table 3 below.
  • PNA probes of SEQ ID NOs: 23 to 30 were prepared, and fluorescence and quenchers were respectively coupled to both ends of the probe sequence for multiple amplification (Table 4).
  • a primer capable of detecting this was prepared using the RNA 150bp region of the Rnase P gene of Homosapiens as a target nucleic acid (Table 5), and the amplification product of the control material was prepared.
  • a detectable PNA probe was prepared (Table 6).
  • the 4S Seasun Smart Shield System
  • the AQ-TOP TM COVID-19 Plus kit it is possible to quickly and accurately determine whether the person is infected with COVID-19, so that the population moves frequently in airports, ports, etc. It is effective for rapid quarantine, large-scale gatherings, and total inspection in areas with mass infection.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un système de quarantaine de COVID-19 utilisant des diagnostics moléculaires basés sur l'amplification isotherme pour détecter le SRAS-CoV-2 et, en particulier, un système de mise en quarantaine dans un aéroport, un port, une zone de rassemblement de grande envergure ou une zone de super contagion. Selon la présente invention, il est possible de tester rapidement et avec précision l'infection à la COVID-19 à grande échelle. La présente invention est ainsi efficace pour la mise en quarantaine d'installations de service de masse, telles que des aéroports, des ports et des gymnases.
PCT/KR2021/008506 2020-07-06 2021-07-05 Système de mise en quarantaine pour maladie infectieuse à haut risque à l'aide d'un diagnostic moléculaire à base d'amplification isotherme WO2022010206A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0082768 2020-07-06
KR1020200082768A KR20220005219A (ko) 2020-07-06 2020-07-06 등온증폭 기반의 분자진단법을 이용한 고위험성 전염병에 대한 검역시스템

Publications (1)

Publication Number Publication Date
WO2022010206A1 true WO2022010206A1 (fr) 2022-01-13

Family

ID=79341927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/008506 WO2022010206A1 (fr) 2020-07-06 2021-07-05 Système de mise en quarantaine pour maladie infectieuse à haut risque à l'aide d'un diagnostic moléculaire à base d'amplification isotherme

Country Status (2)

Country Link
KR (1) KR20220005219A (fr)
WO (1) WO2022010206A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102109196B1 (ko) * 2020-02-11 2020-05-11 대한민국 2019 신종코로나바이러스 검출용 lamp 조성물 및 이의 용도
CN111363860A (zh) * 2020-05-27 2020-07-03 吴江近岸蛋白质科技有限公司 一种检测新型冠状病毒covid-19的核酸组合物及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102109196B1 (ko) * 2020-02-11 2020-05-11 대한민국 2019 신종코로나바이러스 검출용 lamp 조성물 및 이의 용도
CN111363860A (zh) * 2020-05-27 2020-07-03 吴江近岸蛋白质科技有限公司 一种检测新型冠状病毒covid-19的核酸组合物及应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "AQ-TOP™ COVID-19 Rapid Detection Kit Instructions for Use", 1 May 2019 (2019-05-01), pages 1 - 30, XP055886541, Retrieved from the Internet <URL:https://www.fda.gov/media/138307/download> *
ANONYMOUS: "SEASUN BIOMATERIALS to launch COVID-19 Rapid Molecular Assay", 29 April 2020 (2020-04-29), pages 1 - 2, XP055886543, Retrieved from the Internet <URL:https://www.prnewswire.com/in/news-releases/seasun-biomaterials-to-launch-covid-19-rapid-molecular-assay-896502248.html> *
YU FEI; DU LANYING; OJCIUS DAVID M.; PAN CHUNGEN; JIANG SHIBO: "Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China", MICROBES AND INFECTION, vol. 22, no. 2, 1 February 2020 (2020-02-01), FR , pages 74 - 79, XP086085029, ISSN: 1286-4579, DOI: 10.1016/j.micinf.2020.01.003 *

Also Published As

Publication number Publication date
KR20220005219A (ko) 2022-01-13

Similar Documents

Publication Publication Date Title
WO2021162183A1 (fr) Composition lamp pour détecter le nouveau coronavirus 2019 et son utilisation
CN110982943B (zh) 一种新型冠状病毒rt-pcr检测方法及试剂盒
CN112063756B (zh) 多重检测呼吸道病毒核酸的方法及试剂盒
WO2012112012A2 (fr) Kit de diagnostic simultané d&#39;une maladie due à un virus respiratoire
CN113652505B (zh) 检测新型冠状病毒及其voc-202012/01突变株的方法和试剂盒
WO2022005255A2 (fr) Kit et méthode de diagnostic simultané du sars-cov-2 induisant la maladie à coronavirus-19 et du sarbecovirus faisant appel à une sonde pna
WO2022119243A1 (fr) Kit pcr pour diagnostiquer l&#39;asthme ou l&#39;exacerbation de l&#39;asthme et procédé pour fournir des informations pour diagnostiquer l&#39;asthme ou l&#39;exacerbation de l&#39;asthme l&#39;utilisant
WO2022010238A1 (fr) Composition pour la détermination de faux positifs à l&#39;aide d&#39;une séquence nucléotidique artificielle spécifique et procédé de détermination de faux positifs à l&#39;aide de celle-ci
WO2022010206A1 (fr) Système de mise en quarantaine pour maladie infectieuse à haut risque à l&#39;aide d&#39;un diagnostic moléculaire à base d&#39;amplification isotherme
WO2021225221A1 (fr) Kit rt-lamp et procédé de diagnostic d&#39;une infection au coronavirus-19
WO2021075912A1 (fr) Ensemble d&#39;amorces pour une réaction d&#39;amplification multi-isotherme à haute sensibilité capable de cribler et de détecter simultanément mycobacterium tuberculosis et des mycobactéries non tuberculeuses
WO2022145658A1 (fr) Composition pour diagnostiquer une maladie de tsutsugamushi et kit la comprenant
WO2011142646A2 (fr) Procédé de détection de hpv (papillomavirus humain) et de son génotype
CN111549175B (zh) 一种检测口岸输入2019新型冠状病毒多重荧光rt-pcr检测试剂
WO2021141179A1 (fr) Oligonucléotide et plasmide pour la détection simultanée de quatre sérotypes du virus de la dengue, et procédé d&#39;analyse du sérotype du virus de la dengue utilisant celui-ci
Burjanivova et al. Sensitive SARS-CoV-2 detection, air travel Covid-19 testing, variant determination and fast direct PCR detection, using ddPCR and RT-qPCR methods
CN111647683B (zh) 一种新冠状病毒2019-nCoV核酸检测试剂盒及其应用
WO2012002598A1 (fr) Amorce et sonde pour le diagnostic de la tuberculose, trousse comprenant celles-ci et méthode de diagnostic de la tuberculose à l&#39;aide de la trousse
WO2021201601A1 (fr) Sonde anp et amorce pour la détection par rt-lamp du sars-cov-2 provoquant la covid-19 et procédé de détermination d&#39;une infection à l&#39;aide de celles-ci
WO2021215556A1 (fr) Procede de preparation d&#39;un kit de diagnostic de coronavirus, kit de diagnostic de coronavirus ainsi preparé, et procédé de diagnostic de coronavirus l&#39;utilisant
Roy et al. SARS-CoV-2 Detection using Real Time RT PCR by a Commercial Diagnostic Kit
KR20220169639A (ko) 신종 코로나19 바이러스 검역을 위한 현장 진단용 신속분자진단 시스템
WO2024034796A1 (fr) Procédé qpcr pour la détection d&#39;un variant par analyse simultanée de multiples cibles
WO2022114803A1 (fr) Ensemble d&#39;amorces pour identification personnelle et diagnostic d&#39;infection virale respiratoire, et son utilisation
CN114262758B (zh) 检测新型冠状病毒突变株的试剂盒及检测方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838775

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21838775

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21838775

Country of ref document: EP

Kind code of ref document: A1